Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Non Small Cell Lung Carcinoma NSCLC 2NSCLC 2Melanoma 2Triple Negative Breast Neoplasms 1Recurrence 1Primary Breast Cancer 1Non-Small Cell Lung Cancer With HER2- Mutations 1Neoplasm Metastasis 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Docetaxel 3Cyclophosphamide 3Paclitaxel 2Epirubicin 2Tamoxifen 1Fluorouracil 1Doxorubicin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Primary Breast Cancer × CP protocol × Clear all
NCT01314833 2020-05-19

Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

Fudan University

Phase 3 Completed
1,570 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡